For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Tirzepatide - Diabetes Mellitus
PAD Profile : Tirzepatide - Diabetes Mellitus
Traffic Light Status
Status 1 of 1.
- Injection
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves tirzepatide, a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for treating type 2 diabetes in line with the recommendations made in NICE TA924.
Tirzepatide will be given a GREEN traffic light status for this indication.
Dulaglutide remains the preferred choice among GLP-1 options for weekly injections and semaglutide stands as an alternative to dulaglutide for weekly injections.
Please consider tirzepatide as a third line option to dulaglutide and semaglutide weekly injection, only if:
· dulaglutide and semaglutide are unsuitable.
or
the supply of dulaglutide and semaglutide weekly injections is unavailable.